LATISSE (bimatoprost ophthalmic solution) 0.03%

Šalis: Singapūras

kalba: anglų

Šaltinis: HSA (Health Sciences Authority)

Veiklioji medžiaga:

Bimatoprost

Prieinama:

ALLERGAN SINGAPORE PTE. LTD.

ATC kodas:

S01EE03

Dozė:

0.3mg/ml

Vaisto forma:

SOLUTION, STERILE

Vartojimo būdas:

OTHERS

Recepto tipas:

Prescription Only

Pagaminta:

Allergan Sales, LLC

Leidimo data:

2010-08-25

Pakuotės lapelis

Singapore Package Insert 

 1 
_ _

LATISSE
®

(BIMATOPROST OPHTHALMIC SOLUTION) 0.03% 

HIGHLIGHTS OF PRESCRIBING INFORMATION 
These highlights do not include all the information
needed to use LATISSE® safely and effectively. See 
full prescribing information for LATISSE®. 
LATISSE® (bimatoprost ophthalmic solution) 0.03% 
----------------INDICATIONS AND USAGE---------------- 
LATISSE® is a prostaglandin analog,
indicated in adults to treat hypotrichosis of the
eyelashes (upper 
eyelid)
by increasing their growth including length, thickness and darkness.
Efficacy and safety of 
LATISSE® in the treatment of hypotrichosis of the eyelashes
beyond 16 weeks have not been 
investigated. (1) 
----------------DOSAGE AND ADMINISTRATION---------------- 
Apply nightly directly to the skin of the upper eyelid margin
at the base of the eyelashes using the 
accompanying applicators. Blot any excess solution beyond the
eyelid margin. Dispose of the applicator 
after one use. Repeat for the opposite eyelid margin using a new
sterile applicator. (2) 
----------------DOSAGE FORMS AND STRENGTHS---------------- 
Bimatoprost ophthalmic solution 0.3 mg/mL. (3) 
----------------CONTRAINDICATIONS---------------- 
Hypersensitivity. (4.1) 
----------------WARNINGS AND PRECAUTIONS---------------- 
Concurrent administration of LATISSE® and
IOP-lowering prostaglandin analogs in ocular hypertensive  
patients may decrease the IOP-lowering effect. Patients
using these products concomitantly should be 
closely monitored for changes
to their intraocular pressure. (5.1) 
Pigmentation of the eyelids and iris may occur. Iris pigmentation
is likely to be permanent. (5.2, 5.3) 
----------------ADVERSE REACTIONS---------------- 
Most common adverse events (incidence approximately 3% - 4%) are
eye pruritus, conjunctival 
hyperemia, and skin hyperpigmentation. (6) 
SEE 16 FOR PATIENT COUNSELING
INFORMATION